Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.48 |
| ▸ | PRCP | P42785 | 2/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | TLR2 | O60603 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19242291 | 1.00 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3PRCPDPP7 | |
| SCHEMBL26491308 | 1.00 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3PRCPDPP7 | |
| SCHEMBL18791407 | 0.98 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3PRCPDPP7 | |
| SCHEMBL23874154 | 0.98 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3PRCPDPP7 | |
| SCHEMBL21226033 | 0.95 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3PRCP | |
| SCHEMBL24833572 | 0.95 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3PRCP | |
| SCHEMBL24654963 | 0.93 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3PRCPDPP7 | |
| SCHEMBL26488994 | 0.93 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3PRCPDPP7 | |
| SCHEMBL20841352 | 0.92 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3PRCPDPP7 | |
| SCHEMBL21846836 | 0.89 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3PRCPDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230256098-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2023-08-17 | — | — | US | disclosed |
| US-11679158-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11174281-B1 | Modified nucleotides and uses thereof | Singular Genomics Systems, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20190002480-A1 | Silane-Containing Heterocyclic Compounds and Methods of Use Thereof for the Treatment of Viral Diseases | MERCK SHARP & DOHME CORP. (US) | 2019-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11679158-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | SLC6A2 1960/4885SLC6A4 2650/4885SLC6A3 3622/4885 |
| US-20190002480-A1 | Silane-Containing Heterocyclic Compounds and Methods of Use Thereof for the Treatment of Viral Diseases | HAVCR2, SULT2A1, HBB | SLC6A2 4260/4885SLC6A4 4492/4885SLC6A3 4043/4885 |
| US-20230256098-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | SLC6A2 1960/4885SLC6A4 2650/4885SLC6A3 3622/4885 |
| US-11174281-B1 | Modified nucleotides and uses thereof | NUDT1, RNMT, ADAR | SLC6A2 1760/4885SLC6A4 1692/4885SLC6A3 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.